Get started
Author

Laura Pearce

Trends in the global immuno-oncology landscape
2018 · Jun Tang, Laura Pearce, et al. · Nature Reviews Drug Discovery · 150
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study
2006 · Eric Winquist, Jennifer Knox, et al. · Investigational New Drugs · 134
The global landscape of cancer cell therapy
2018 · Jun Tang, Vanessa M. Hubbard-Lucey, et al. · Nature Reviews Drug Discovery · 74
Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19
2004 · Leonard Reyno, Lesley Seymour, et al. · Journal of Clinical Oncology · 62
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer
2021 · Andrew DJ. Pearson, Claudia Rossig, et al. · European Journal of Cancer · 39
PDF
Erratum: Trends in the global immuno-oncology landscape
2018 · Jun Tang, Laura Pearce, et al. · Nature Reviews Drug Discovery · 37
PDF
Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS)
2006 · G. Garcia-Manero, M. Minden, et al. · Journal of Clinical Oncology · 17
IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).
2021 · Sandra P. D'Angelo, Jonathan Christopher Noujaim, et al. · Journal of Clinical Oncology · 10
Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products
2024 · Mark D. Stewart, Michael Kalos, et al. · Cytotherapy · 4
PDF
Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO).
2020 · Sandra P. D'Angelo, Jean-Yves Blay, et al. · Journal of Clinical Oncology · 2
Abstract B207: Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE
2019 · Naiyer Rizvi, Patricia Tang, et al. · Cancer Immunology Research · 1
PA-144 Development of BCMA-Specific TAC-T Cells: Enabling TACtful, a First-in-Human Study in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
2026 · Laura Pearce, Joanne A. Hammill, et al. · Clinical Lymphoma Myeloma & Leukemia
Abstract CT239: IND.241: A Canadian cancer trials group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast cancer
2025 · Moira Rushton, Dave W. Cescon, et al. · Cancer Research
Abstract A019: Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies
2019 · Jun Tang, Laura Pearce, et al. · Cancer Immunology Research
Works count: 14
Citation count: 530
H-index: 8
I10-index: 8
Year
Topic
Type